The opinion piece published in this edition of the European Heart Journal by Leening and colleagues 1 represents one of the two main opposing views on the role of age in cardiovascular disease (CVD) risk prediction scores and for determining risk-reducing treatment thresholds. Leening et al. raise concerns about the dominance of age in CVD risk prediction scores and propose the use of two new risk metrics that do not rely on age. In contrast Wald and colleagues have advocated that for simplicity, age, rather than multivariable predicted risk, should be the sole criterion used to determine eligibility for treatment.
In our opinion both positions are problematic. We agree with Wald et al. that age is the single best predictor of a patient's short-term (e.g. 5-or 10-year) CVD risk and is also the single best predictor of the short-term benefits of CVD risk reduction. 2 However, we disagree that the simplicity of an age-only treatment threshold would outweigh the incremental improvement in predictive power and the greater acceptability (to patients and clinicians) of risk prediction scores that include the standard modifiable CVD risk factors alongside age. We also disagree with Leening and colleagues that the dominant role of age in CVD risk prediction calculators is a problem because, as stated above, age is best single predictor of future CVD risk and treatment benefit. We acknowledge the concerns that they and many others have regarding the apparent dominance of age in CVD risk prediction, but we disagree with their assumptions about the role of age in CVD risk prediction and about how predicted CVD risk should be used to inform management decisions.
In this counter Current Opinion article, we address the three questions posed by Leening et al. (i) Should all healthy older aged persons be treated in the absence of risk factors? (ii) Is it possible to identify younger persons at low short-term risk but high long-term risk? (iii) Can the contribution of cardiovascular risk factors to overall CVD risk be more effectively communicated using metrics that do not rely on age? To help address these questions we explain why we believe that age should remain a central component of CVD risk prediction and how we have addressed concerns about the role of age, by integrating two complementary risk metrics, both including age, to better communicate CVD risk.
Healthy older age, optimal risk factor levels, and cardiovascular disease risk prediction
There is an assumption among some commentators and clinicians that the age term in CVD risk prediction scores reflects an independent effect of age on risk. Rather, age is largely a proxy for length of exposure to modifiable CVD risk factors. As most risk factors track over a person's lifetime, 3 the combination of a risk factor measure and age is a way of integrating exposure burden at that age. For example, 'pack-years' of smoking is a better predictor of CVD risk than current cigarette consumption; 4 however, for ease of use in busy clinical practice, the modifiable CVD risk factors incorporated into CVD risk prediction scores are usually based on cross-sectional measures made at the time of assessment (e.g. current blood pressure, current blood lipids, and current smoking status). 5, 6 Therefore, downgrading age in risk prediction scores would downgrade the best current measure we have of cumulative exposure to modifiable CVD risk factors. Inextricably linked to this assumption that age is an independent CVD risk factor is the concern that many healthy older individuals now eligible for drug treatment based on their predicted short-term
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CVD risk have no other risk factors. In fact, the vast majority of these people have sub-optimal levels of the common CVD risk factors. For example, when Leening and colleagues argue that 'otherwise healthy older adults with minimal or no risk factors are now considered candidates for statin treatment solely by virtue of their age,' they support their statement of 'minimal or no risk factors' using definitions of 'optimal LDL' (≤2.5 mmol/L or ≤97 mg/dL) commonly used in guidelines. 1 Yet, as they later acknowledge, this is not the same as having 'no risk factors.' Indeed, it is widely accepted that the ideal LDL cholesterol range is probably 50 -70 mg/dL, which are the levels found in 'native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals,' 7 but seldom in middle-aged Americans or Europeans, unless they are already on statins. Moreover, randomized trials have yet to find a lower limit of LDL cholesterol below which there is no further treatment benefit. 8 Therefore, a strategy of recommending statins to 'healthy' older people with average or even below average LDL cholesterol levels is an effective means of reducing their CVD risk.
The two fundamental features of CVD risk-that age is a proxy for length of exposure to modifiable CVD risk factors and that typically defined 'optimal' CVD risk factor levels are not biologically ideal levels-are also illustrated in Figure 1 in relation to systolic blood pressure (SBP). The data presented in the figure come from an individual person meta-analysis of over 900 000 participants in 61 cohort studies with 12 years follow-up and shows the association between increasing SBP and ischaemic heart disease (IHD) mortality by age group. 9 The vertical axis in the figure uses a floating absolute risk scale because the data combine multiple cohort studies with different IHD mortality rates. As a useful reference point, one unit on this scale is approximately equivalent to about a 1% 10-year CVD event rate in UK males with an SBP of 140 mmHg.
10 Figure 1 demonstrates that the optimal SBP in these populations, mainly from Europe (70%) and North America (20%), is 115 -120 mmHg across a wide age range. This is lower than generally accepted 'normal' or 'optimal' blood pressure levels of 120 -130 mmHg and the vast majority of middle-aged and older people in North America and Europe, who are not already on blood pressure-lowering medications, have SBP levels .120 mmHg.
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Figure 1 also demonstrates the clinical significance of integrating age and blood pressure when estimating blood pressure-related CVD risk. For example the absolute risk of IHD mortality among 40-to 49-year-old males with an SBP of 140 mmHg was 3 units, which doubled to 6 units if the SBP was 160 mmHg. So the observed absolute 'SBP effect' on IHD risk can be estimated as the absolute difference between these two risks (i.e. 6-3 ¼ 3 absolute risk units). In contrast, the equivalent absolute risks among 60 -69 years old were 18 units (for SBP ¼ 140 mmHg) and 32 units (for SBP ¼ 160 mmHg), so the absolute 'SBP effect' in this older age group was 32-12 ¼ 14 absolute risk units, but the relative doubling of risk remained approximately the same as for 40-49 years old.
In other words, an SBP difference of 20 mmHg has a considerably greater absolute effect on IHD risk in the older compared with the younger group, much of which can be explained by the additional 20 years of exposure to a higher blood pressure. This would be missed if age was downgraded or removed from the calculation of risk and only the relative doubling of risk in the two age groups was reported. Moreover, a recently published individual metaanalysis of RCTs of blood pressure-lowering drugs demonstrates that the absolute CVD-related benefits of blood pressure-lowering drug treatment are directly proportional to a person's pre-treatment absolute CVD risk. 12 Therefore, downgrading age in a CVD risk equation would undermine the ability of a risk score to predict either absolute risk or absolute treatment benefits and leave clinicians and their patients in the dark about the true risks and benefits.
Younger age, multiple risk factors, and risk management decisions
The other important concern, raised by Leening et al. about the dominance of age in risk scores relates to the low-predicted shortterm absolute CVD risk in most young people with high levels of modifiable CVD risk factors. Yet these patients are frequently considered to be 'ticking time bombs.' The reason these young patients do not meet drug treatment criteria is because their 5-or 10-year absolute CVD risks are low due to the short time they have been exposed to raised risk factor levels, so any benefits of drugs over the next 5-10 years will also be small. However, the fact that shortterm risk measures do not address this very real concern about the longer-term risk in these young patients is not due to the dominance of age in absolute risk prediction scores. Rather, it is due to our inability to communicate the important harms of modifiable risk factors or the benefits of interventions in younger people, when we use short-term risk alone. 14 The reason they continue to do so is because they also know that the background absolute risk of VT is 1-2 per 10 000 women-years. A 3-fold increase in this small absolute risk is still very small, particularly when compared with the absolute risks associated with even normal pregnancies. Therefore, we do not support the new relative risk-based metrics proposed by Leening et al.
So how should we address the apparent problem of lowpredicted short-term CVD risk in young patients with high levels of modifiable risk factors and therefore high longer-term risk?
Firstly, as discussed above, short-term absolute CVD risk measures should primarily be used to inform the intensity and timing of different types of risk management, whereas in current practice they are typically misused as a yes -no drug treatment decisionmaking metric. As almost all adult patients in western countries have high lifetime CVD risk, every adult patient needs their CVD risk managed every time they see a clinician. If the predicted shortterm absolute risk is high, then intensive interventions, sometimes with drugs may be appropriate to rapidly reduce this absolute risk. However, if the short-term risk is low, then any short-term drug treatment effects will also be small and the patient has time to try less intensive, non-pharmacological interventions, before embarking on life-long daily drug treatment.
Secondly, risk needs to be communicated in ways that enable patients to understand the importance of modifying their behaviour, even when their short-term risk is low. To achieve this, a number of groups have already developed heart age tools. 5, 15 Our version, the interactive Heart Age Forecast, integrates the predicted shortterm risk with a calculated heart age 16 and is illustrated in Figures 2-4 .
The first step involves calculating a patient's 5-year CVD risk (note: in New Zealand, we currently use a 5-year risk calculated using a modified Framingham Heart Study risk score). The patient is shown a screen with their predicted 5-year risk (a pulsating red dot), as illustrated in Figure 2 by the 6% 5-year risk in a 45-year-old nonsmoking male with an SBP of 150 mmHg and total cholesterol to high-density lipoprotein cholesterol ratio of 6.0. 17 On the next screen (Figure 3) , the patient is shown the blue line, which forecasts the predicted 5-year CVD risk at all ages between 35 and 75 years for a male with typically defined 'optimal' risk factor levels. If a vertical line was drawn from the patient's current short-term CVD risk to the blue line, this would represent the absolute CVD risk difference between the patient's current risk and their ideal current risk (6 2 2% ¼ 4% in the example given) and quantifies the adverse effect of modifiable risk factors right now. The next screen ( Figure 4 ) provides a context for this absolute risk difference by explicitly drawing a horizontal line from the patient's current short-term risk to the blue line, to estimate the patient's 'heart age' (60 years in the example). This is the age at which the patient would be expected to have their current 5-year risk, if they had optimal risk factor levels. Subsequent screens (not shown here) forecast what would happen to the patient's 5-year risk over their lifetime if they do not modify their current risk factor status and what the impact of changing individual risk factors would have on their future 5-year risk. 17 We recommend that clinicians and patients continue to use the predicted short-term absolute CVD risk (Figure 2 ) to decide whether intensive risk factor management should be initiated in the near future to rapidly reduce a high short-term risk. Randomized control trials indicate that a combination of several blood pressurelowering drugs and statins could at least halve this patient's risk from about 6 to 3% in 5 years, 18 so about 33 patients like him would need to take these drugs for 5 years to prevent one CVD event. However, we also recommend using the linked 'heart age gap' (60 -45 years ¼ 15 years in the example) to help the patient understand what this risk means. It is an alternative way of describing the magnitude of the patient's short-term absolute risk and provides more contextual information on the potential benefits of lifestyle changes, particularly when they are also shown their risk trajectory if they do not make any changes. Some younger patients will consider a small predicted short-term absolute benefit of drug treatment worthwhile, particularly if their heart age gap is large. Moreover, given their safety and low cost, UK NICE guidelines have recently halved recommended absolute risk threshold for considering statins. 19 With similar treatment thresholds now recommended in the USA, 20 many younger patients now meet recommended treatment criteria. However, we believe that when a patient meets a recommended drug treatment threshold, it should trigger a comprehensive discussion about the risks of not starting treatment and about the likely benefits of starting treatment using both a short-term absolute risk metric and a heart age or equivalent metric. Given that a decision to start drug treatment is generally a decision for life, patients should be fully informed using appropriate and understandable measures.
Conclusion
Age is the dominant variable in CVD risk prediction scores largely because it is a proxy for the length of time patients are exposed to modifiable risk factors, rather than being primarily a CVD risk factor in its own right. So downgrading the role of age would paradoxically downgrade the predictive power of a risk score. Moreover, the concern that many older patients will be eligible for drug treatment solely because of their age is unfounded because most of these people do not have optimal levels of common modifiable risk factors and most would benefit from treatment. Absolute risk-based drug treatment thresholds may have been set too low in recent guidelines, but this is a separate issue and not due to the dominance of age in risk prediction scores. All risk management decisions should be informed by predicted absolute measures of risks and benefits, and not by relative risk measures, which are clinically meaningless unless the absolute risks of reference groups are also known. The doubling or trebling of a very small risk will still be very small, whereas a 20% change in a very large risk could be clinically significant.
The magnitude of the predicted short-term absolute risk is the best predictor of the magnitude of short-term treatment benefits and should be used to inform decisions about the intensity and timing of interventions, rather than whether to intervene or not. However, this short-term risk metric alone provides insufficient information on the potential longer-term risks and longer-term benefits of interventions in younger patients with high levels of modifiable risk factors, but low current short-term risks. Using the Heart Forecast tool has helped us and our colleagues communicate risk with our patients. Heart age has been shown to be a useful risk communication metric elsewhere 15 but would benefit from further evaluation and development. The 'heart age gap' between a person's current chronological age and their calculated heart age as well as their forecasted future short-term risk over their lifetime if they do not modify their risk factors, are useful ways to motivate behaviour change.
